AbbVie’s anti-inflammatory blockbuster Humira accounted for nearly $1.4 billion in additional unsupported U.S. drug spending last year, the Institute for Clinical and Economic Review says.

Drug Pricing Watchdog Identifies Most Significant Price Hikes

Makers of seven of 10 top drugs in the U.S. hiked those drugs’ prices substantially in 2020 with no new evidence of improved safety or effectiveness, led by AbbVie’s anti-inflammatory blockbuster Humira, an influential drug pricing watchdog group says.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report